AMDG, a UK-based company, has invented a heart monitor for early detection of heart conditions which are particularly associated with diabetics. With the product already selling in Germany, it is now looking to enter into the US market.
AMDG’s VariaCardio TF5 monitor is designed to detect cardiac autonomic neuropathy (CAN) and diabetic autonomic neuropathy (DAN), conditions that are particularly associated with diabetics. These conditions could lead to heart failure and affect 70 per cent of the 1.4 million diabetics in the UK, according to the company.
CAN and DAN can be controlled by a new class of drugs known as piogliazones if used early enough. But piogliazones are ineffective once clinical signs become apparent. The TF5 can help easily detect CAN and DAN at a very early stage, the company says.
The Leeds-based company, which was founded in 1999, is looking for investment of £400,000 to establish marketing and sales activity in the US. The company said it aims to become a global market leader, either with a partner (or partners) or through individual countrywide or regional distribution agencies.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
